DNA Plasmid Vaccine
Showing 1 - 25 of >10,000
Prostate Cancer, Bladder Cancer, NSCLC Trial in New York, Houston (NY-ESO-1 Plasmid DNA Cancer Vaccine)
Completed
- Prostate Cancer
- +4 more
- NY-ESO-1 Plasmid DNA Cancer Vaccine
-
New York, New York
- +1 more
Oct 3, 2022
Chronic Hepatitis, Hepatitis C Infection Trial in Puerto Rico, United States (Electroporation-Mediated Plasmid DNA Vaccine
Active, not recruiting
- Chronic Hepatitis
- Hepatitis C Infection
- Electroporation-Mediated Plasmid DNA Vaccine Therapy
- +4 more
-
Jacksonville, Florida
- +4 more
Sep 20, 2022
Hormone-Resistant Prostate Cancer, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Tumor in the Soft Tissues Trial
Active, not recruiting
- Hormone-Resistant Prostate Cancer
- +6 more
- Pembrolizumab
- pTVG-HP Plasmid DNA Vaccine
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Nov 8, 2022
HIV Trial in Kampala (VRC-HIVDNA009-00-VP, Placebo vaccine)
Completed
- HIV Infections
- VRC-HIVDNA009-00-VP
- Placebo vaccine
-
Kampala, UgandaMakerere University Walter Reed Project (MUWRP)
Oct 28, 2021
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck
Terminated
- Metastatic Head and Neck Squamous Cell Carcinoma
- +2 more
- ImmunoPulse
- +4 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Sep 1, 2022
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Seattle
Not yet recruiting
- Lung Non-Squamous Non-Small Cell Carcinoma
- +3 more
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
- Sargramostim
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 11, 2022
HIV Trial in Birmingham, San Francisco, Seattle (pGA2/JS2 Plasmid DNA Vaccine)
Completed
- HIV Infections
- pGA2/JS2 Plasmid DNA Vaccine
-
Birmingham, Alabama
- +3 more
Oct 13, 2021
HIV Trial in Kericho (Env-C Plasmid DNA, HIV Env gp145 C.6980 protein, Rehydragel®)
Active, not recruiting
- HIV Infections
- Env-C Plasmid DNA
- +6 more
-
Kericho, KenyaKenya Medical Research Institute/Walter Reed Project, Clinical R
Feb 25, 2022
HIV Trial in United States (DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine )
Terminated
- HIV Infections
- DNA plasmid vaccine
- +3 more
-
Birmingham, Alabama
- +21 more
Oct 13, 2021
HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer Trial in Seattle
Recruiting
- HER2 Negative Breast Carcinoma
- +6 more
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
- Laboratory Biomarker Analysis
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Feb 18, 2022
HIV-1-infection Trial in Los Angeles, San Francisco (PENNVAX-GP, INO-6145, INO-9012)
Completed
- HIV-1-infection
- PENNVAX-GP
- +3 more
-
Los Angeles, California
- +1 more
Apr 4, 2022
HIV Trial in Kampala (VRC-HIVADV014-00-VP Vaccine)
Completed
- HIV Infections
- VRC-HIVADV014-00-VP Vaccine
-
Kampala, UgandaMakerere University Walter Reed Project (MUWRP)
Oct 28, 2021
SARS-CoV-2 Trial in Worldwide (Covigenix VAX-001 , Covigenix VAX-001)
Recruiting
- SARS-CoV-2
- Covigenix VAX-001 placebo
- Covigenix VAX-001
-
Ouagadougou, Burkina Faso
- +4 more
Jul 23, 2022
Advanced Ovarian Cancer Trial in Seattle (AST-201, Paclitaxel, Carboplatin)
Not yet recruiting
- Advanced Ovarian Cancer
- AST-201
- +4 more
-
Seattle, WashingtonUniversity of Washington
Mar 20, 2023
HIV Trial (VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP )
Withdrawn
- HIV Infections
- VRC-HIVDNA016-00-VP
- +3 more
- (no location specified)
Oct 28, 2021
Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 Trial
Not yet recruiting
- Anatomic Stage IB Breast Cancer AJCC v8
- +16 more
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
- Sargramostim
-
Seattle, Washington
- +1 more
Jul 27, 2022
HIV Trial in Boston, Seattle (HIV-1 DNA plasmid vaccine, HIV-1 recombinant Ad5 vaccine)
Completed
- HIV Infections
- HIV-1 DNA plasmid vaccine
- HIV-1 recombinant Ad5 vaccine
-
Boston, Massachusetts
- +1 more
Oct 13, 2021
HIV Trial in United States (PENNVAX®-GP HIV-1 DNA vaccine, Interleukin-12 (IL-12) DNA adjuvant, Placebo)
Completed
- HIV Infections
- PENNVAX®-GP HIV-1 DNA vaccine
- +2 more
-
Decatur, Georgia
- +3 more
Oct 13, 2021
Sars-CoV-2 Infection Trial in South Africa (Alveavax-v1.2, Janssen Ad26.COV2.S)
Completed
- Sars-CoV-2 Infection
- Alveavax-v1.2
- Janssen Ad26.COV2.S
-
Bloemfontein, Free State, South Africa
- +7 more
May 2, 2023
COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2, COVID-19 Immunisation Trial in Italy (COVID-eVax,
Active, not recruiting
- COVID-19
- +2 more
- COVID-eVax
- Cliniporator® and EPSGun
-
Monza, Italy
- +3 more
Dec 20, 2021
HIV Trial in Boston (env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant)
Active, not recruiting
- HIV Infections
- env (A,B,C,A/E)/gag (C) DNA Vaccine
- +3 more
-
Boston, MassachusettsBrigham and Women's Hospital
Jun 8, 2022
HCC Trial in Baltimore, New York, Auckland (biological, drug, device)
Recruiting
- HCC
- GNOS-PV02
- +3 more
-
Baltimore, Maryland
- +2 more
Apr 26, 2022
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Tumor Trial in Houston (DNA
Active, not recruiting
- Human Papillomavirus-16 Positive
- +20 more
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
- Durvalumab
-
Houston, TexasM D Anderson Cancer Center
Feb 11, 2022
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV Trial in Tampa (IFx-Hu2.0)
Completed
- Cutaneous Melanoma, Stage III
- Cutaneous Melanoma, Stage IV
- IFx-Hu2.0
-
Tampa, FloridaH. Lee Moffitt Cancer Center
Aug 5, 2022